Novo Nordisk Downgrade to Sell by Deutsche Bank
Novo Nordisk downgrade by Deutsche Bank cut the target, citing slowing 2027 growth, pipeline failure and patent-cliff risk, pressuring shares.
KEY TAKEAWAYS
- Deutsche Bank cut Novo Nordisk to sell and lowered its target to DKK 265 after trimming medium-term sales.
- The bank warned Novo Nordisk may not return to growth in 2027 and flagged a large patent-cliff risk.
- Analysts tied the downgrade to pipeline setbacks after ziltivekimab failed and intensifying Eli Lilly competition.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Novo Nordisk was downgraded to sell by Deutsche Bank on Aug. 27, 2026, with its price target cut to DKK 265. The bank cited slowing growth prospects for 2027, pipeline setbacks including the failure of ziltivekimab, and longer-term patent-cliff risk, pressuring the stock.
Deutsche Bank Downgrade and Growth Concerns
Deutsche Bank lowered Novo Nordisk to sell from hold, attributing the call to analyst Emmanuel Papadakis. The bank trimmed its medium-term sales forecasts and linked the reduced target to those revisions. It expressed doubt that the company will return to growth in 2027 and said upside from U.S. Medicare prescriptions appears limited.
The bank also flagged a significant patent cliff later in the decade as a material downside risk. It noted that ziltivekimab, a drug in late-stage development, no longer supports the growth outlook after failing to reduce heart-attack or stroke risk in a recent trial.
Competitive and Pipeline Pressures
Market commentary connected the downgrade to intensifying competition from Eli Lilly and the emergence of copycat versions of Novo Nordisk’s Ozempic and Wegovy products. Shares fell roughly 2% on the day, with some venues reporting declines near 2.5%. The stock has dropped about 70% since its June 2024 peak.
The downgrade followed a mixed second-quarter update earlier in August, reflecting ongoing uncertainty about the company’s near-term trajectory amid these challenges.
